Media Releases

1 July, 2022

From today, 1 July 2022, anyone eligible for a Cervical Screening Test under the NCSP (i.e. women and people with a cervix aged 25-74 years who have ever had any sexual contact) will have the choice to screen either through self-collection of a vaginal sample using a simple swab (unless a co-test is indicated), or clinician-collection of a sample from the cervix using a speculum.

31 May, 2022

In a new position statement released today, the Royal College of Pathologists of Australasia (RCPA) advises that serology testing has limited use in the diagnosis of COVID-19. If serology testing must be performed, the RCPA recommends that only laboratory-based assays are used due to their higher sensitivity and specificity and the current lack of a clinical or public health need for rapid point-of-care SARS-CoV-2 serology testing.

25 May, 2022

The Royal College of Pathologists of Australasia (RCPA) is concerned that the uptake of COVID-19 boosters (the third vaccine dose) has slowed considerably in all States and is particularly low in Queensland and New South Wales. With COVID-19 cases on the rise, the RCPA is encouraging all eligible individuals to get a COVID-19 booster at their earliest convenience. Influenza vaccines can and should be administered safely at the same time as the COVID-19 booster.

26 April, 2022

Due to a low uptake of influenza vaccines in 2021, and the very low circulation of influenza virus globally over the past two years, the Royal College of Pathologists of Australasia (RCPA) warns that Australians are more likely to be vulnerable to influenza this year. Despite vaccination fatigue, the RCPA recommends anyone aged six months and over to get the influenza vaccine in order to prevent widespread illness and even deaths from influenza. Those who have not received their COVID-19 vaccine or are eligible for a booster or “winter dose” are encouraged to get both vaccines at the same time.

28 March, 2022

Following an application by the Royal College of Pathologists of Australasia (RCPA) to the Medical Services Advisory Committee (MSAC), reproductive carrier screening for fragile X syndrome (FXS), spinal muscular atrophy (SMA) and cystic fibrosis (CF) will be listed on the Medicare Benefits Schedule (MBS). The funding forms part of the 2022/23 Federal Budget which is being announced this week.

4 March, 2022

The Royal College of Pathologists of Australasia (RCPA) supports the move to add Braftovi, a targeted therapy for metastatic colorectal cancer (mCRC) to the Pharmaceutical Benefits Schedule (PBS) this year, improving health outcomes for potentially thousands of patients in Australia.

7 February, 2022

The Royal College of Pathologists of Australasia (RCPA), which oversees the quality of diagnostic testing in Australia and New Zealand, has released a new position statement on COVID-19 Antigen and Point of Care Testing (POCT). The new position statement recognises Australia’s changed circumstances of having a high prevalence of COVID-19 infections after the Omicron surge, and the approval of self-testing (home use) by the Therapeutic Goods Administration (TGA).

5 January, 2022

The Royal College of Pathologists of Australasia (RCPA) strongly recommends that PCR tests are now only available for: patients who are unwell; or, those who have been advised to do so by the Health Department.

At the present time, most laboratories have exceeded their testing capacity. This has happened for three reasons: the increased volume of testing; a change in how laboratories can now test due to a higher number of positive PCR results; and staff shortages.

29 December, 2021

The Royal College of Pathologists of Australasia (RCPA) continues to proudly support our pathology fellows and senior scientists wherever possible through our role in training, con-tinuing professional development, quality and professional standards, to help them to pro-vide the highest standards of pathology testing to all Australians.

18 November, 2021

This month, three new items will be added to the Medicare Benefits Schedule (MBS) following several applications by the Royal College of Pathologists of Australasia (RCPA) to the Medical Services Advisory Committee (MSAC). The items include genetic testing for certain blood cell cancers and for pregnancies with major fetal structural abnormalities, and diagnostic testing for neuromyelitis (NMO). It is expected that these additions will improve access to life changing pathology services for approximately 22-23,000 patients per year.

Displaying results 1 - 10 of 82

Page last updated:

Copyright © 2022 RCPA. All rights reserved.